Skip to content

Bimagrumab

Also called Anti-activin type II receptor antibody

A monoclonal antibody that blocks the activin type II receptor, preventing myostatin and activin from signaling.

  • TypePeptide
  • FormOther
  • Researched forMetabolic & Fat Loss
Join Skool for the protocol

No partner carries Bimagrumab yet.

The short version

  • Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
  • What the evidence isReached phase 2 with a genuinely unusual result.
  • What to watchCramps severe enough to wake you.

How Bimagrumab works

Bimagrumab is a monoclonal antibody that blocks a receptor rather than neutralizing a ligand, and that single design decision is why its effect is larger than every myostatin antibody that came before it.

The pathway. Myostatin, activin A and several related TGF-beta superfamily ligands do not each have their own receptor. They converge on the activin type II receptors, ActRIIA and ActRIIB, which then recruit a type I receptor (ALK4 or ALK5) and phosphorylate Smad2 and Smad3.

Blocking that pathway removes the brake on muscle growth — the result in trials is simultaneous fat loss and lean mass GAIN, which is close to unique and is exactly why it's being studied alongside GLP-1s, where muscle loss is the main criticism.

  • Other

On the goal map: Lean-mass protection while cutting (Lose fat)

Can you get Bimagrumab?

No partner sells it, and this page won’t pretend otherwise.

A discontinued Novartis investigational antibody. It was never approved, no pharmacy dispenses it, and no telehealth service can prescribe it. Here because the myostatin data is genuinely interesting — not because you can get it.

Research on Bimagrumab7 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Human clinical evidence

  • Reached phase 2 with a genuinely unusual result. A randomized trial in obese adults with type 2 diabetes reported roughly 20% loss of fat mass alongside a ~4% gain in lean mass over 48 weeks — body recomposition, not weight loss, and the scale weight barely moved.

  • It failed its earlier target indications. A phase 2b/3 in sporadic inclusion body myositis missed its primary endpoint despite increasing muscle mass — a clean example of mass without function, which is the single most important caveat about this mechanism.

Correlative data

  • No marketed use; it was acquired by Eli Lilly and is being studied in combination with tirzepatide, on the logic that it addresses GLP-1's lean-mass problem.

  • Trial adverse effects were mostly muscle cramps, diarrhea and acne. Long-term data does not exist.

How the mechanism reads

  • A monoclonal antibody blocking the activin type II receptor, which is the shared receptor for myostatin and the activins — the negative regulators of muscle mass. Block the receptor and you remove the brake.

    Mechanistic
  • Blocking the receptor rather than one ligand is the design choice, and it is why the effect is larger than myostatin inhibition alone: several ligands converge there.

    Mechanistic
  • The IBM failure is the mechanism's own warning. Removing a growth brake adds tissue; it does not guarantee that tissue is functional or well-innervated. And ActRII signaling does other things — the same pathway is involved in bone and reproductive biology.

    Mechanistic

Sources

  • Heymsfield SB, et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Network Open 2021 · PMID 33439265
  • Amato AA, et al. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology 2021 · PMID 33597289
  • Heymsfield SB, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nature Medicine 2026 · PMID 41772149
  • Shao C, et al. Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes, Obesity and Metabolism 2026 · PMID 42530342
  • Rodgers BD, Ward CW. Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs. Endocrine Reviews 2022 · PMID 34520530

Bimagrumab safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Active cancer, since activin and myostatin signaling restrain cell growth.
  • Pregnancy, because activin type II receptors guide fetal tissue patterning.
  • Under 18, while bone and muscle growth are still regulated by these ligands.
  • Bleeding disorders or anticoagulant use, given nosebleeds with related ligand-blocking drugs.
  • Chronic diarrhea or gut disease.

What’s expected

  • Muscle spasms and cramps, quantified at about ten times placebo in pooled trials.
  • Diarrhea and some acne.
  • Lean mass gain with fat loss, which almost no other drug class does.

Watch for

  • Cramps severe enough to wake you.
  • Diarrhea that persists with weight loss.
  • Tendon pain as muscle outgrows its tendon.

Labs that tell you it’s working

  • Comprehensive Metabolic Panel: muscle growth moves creatinine, AST and ALT without liver or kidney harm.
  • Cystatin C with eGFR: a kidney read that extra muscle cannot distort.
  • HbA1c: trials showed insulin sensitivity improving as fat fell.
  • LH & FSH: activin blockade can pull FSH down.

Monoclonal antibody against activin type II receptors, blocking myostatin and activin signaling; adverse effects follow from that pathway. PMID 33439265 PMID 42530342

Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON

Bimagrumab FAQ4 common questions

Is Bimagrumab approved for human use?
No. Bimagrumab is a research compound.
What is Bimagrumab researched for?
Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Which labs show whether it's doing anything?
Comprehensive Metabolic Panel; Cystatin C with eGFR; HbA1c; LH & FSH: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for Bimagrumab: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what Bimagrumab is. Skool covers how it is run.

Free on this page

What Bimagrumab is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What Bimagrumab is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Join Skool for the protocol